Dickkopf家族蛋白在非小细胞肺癌中的作用机制和治疗应用的研究进展

doi:10.11904/j.issn.1002-3070.2021.01.013

摘要/Abstract

摘要： 非小细胞肺癌(Non-small cell lung cancer,NSCLC)占所有肺癌的80%~85%,是全世界发病率和致死率极高的恶性肿瘤。最初NSCLC对现有治疗的反应良好,但最终还是产生了耐药性。因此,有必要探索有效且新颖的治疗方法。随着对NSCLC研究的深入,发现Dickkopf家族蛋白(DKKs)的信号传导在NSCLC发展中扮演重要角色,DKKs是Wnt/β-catenin信号通路的重要调节因子,并与NSCLC细胞增殖、转移和侵袭密切相关。本文主要介绍了DKKs家族成员在NSCLC中的作用机制,讨论了DKKs在NSCLC治疗中的潜力,为进一步防治NSCLC提供了新思路。

关键词: 非小细胞肺癌, Dickkopf家族蛋白(DKKs), Wnt/β-catenin通路

Abstract: Non-small cell lung cancer(NSCLC)accounts for 80% to 85% of all lung cancers,and it is a malignant tumor with extremely high morbidity and mortality over the world.Initially,NSCLC has responded well to existing treatments,but it eventually has developed resistance.Therefore,it is necessary to explore effective and novel treatment methods.With the in-depth study of NSCLC,it is found that Dickkopf family protein(DKKs)signaling plays an important role in the development of NSCLC.DKKs are important regulators of the Wnt/β-catenin signaling pathway and are closely related to proliferation,metastasis and invasion of NSCLC cells.This article mainly introduces the mechanism of DKKs family members in NSCLC,discusses the potential of DKKs in the treatment of NSCLC,and provides new ideas for the further prevention and treatment of NSCLC.

Key words: Non-small cell lung cancer, Dickkopfs family proteins(DKKs), Wnt/β-catenin pathway

中图分类号:

R734.2

董程(综述),段勇(审校). Dickkopf家族蛋白在非小细胞肺癌中的作用机制和
治疗应用的研究进展[J]. 实用肿瘤学杂志, 2021, 35(1): 64-68.

DONG Cheng,DUAN Yong. Research progress on the mechanism and treatment of Dickkopf family protein in non-small cell lung cancer[J]. Journal of Practical Oncology, 2021, 35(1): 64-68.

参考文献

1 Bozinovski S,Vlahos R,Anthony D,et al.COPD and squamous cell lung cancer:aberrant inflammation and immunity is the common link[J].Br J Pharmacol,2016,173(4):635-648.
2 Herbst RS,Morgensztern D,Boshoff C.The biology and management of non-small cell lung cancer[J].Nature,2018,553(7689):446-454.
3 蔡静,候玥.非小细胞肺癌患者血清miR-195的表达及其临床意义[J].实用肿瘤学杂志,2018,32(5):415-419.
4 黄本林,段勇.免疫检查点抑制剂在小细胞肺癌治疗中的临床研究进展[J].中国肺癌杂志,2019,22(4):239-244.
5 Yeung K,Carlson JJ.Clinical and economic review of erlotinib in non-small-cell lung cancer[J].Expert Rev Pharmacoecon Outcomes Res,2012,12(4):411-423.
6 Hirsch FR,Suda K,Wiens J,et al.New and emerging targeted treatments in advanced non-small-cell lung cancer[J].Lancet,2016,388(10048):1012-1024.
7 Heymach J,Krilov L,Alberg A,et al.Clinical cancer advances 2018:annual report on progress against cancer from the American society of clinical oncology[J].J Clin Oncol,2018,36(10):1020-1044.
8 Song Z,Wang H,Zhang S.Negative regulators of Wnt signaling in non-small cell lung cancer:theoretical basis and therapeutic potency[J].Biomed Pharmacother,2019,118,109336.
9 姚伶俐.DKK1在非小细胞肺癌血管生成拟态形成中的作用研究[D].天津:天津医科大学,2014.
10 Veeck J,Dahl E.Targeting the Wnt pathway in cancer:the emerging role of Dickkopf-3[J].Biochim Biophys Acta,2012,1825(1):18-28.
11 谢兰丰,沈思兰,钱方兴.Wnt信号通路抑制剂Dickkopf-3的研究进展[J].肝脏,2018,23(10):925-928.
12 张艳萍,刘昊凌.DKK1在糖尿病血管病变中的研究进展[J].医学综述,2017,23(15):3068-3071.
13 Gao Y,Du X,Zeng J,et al.Prediction and identification of transcriptional regulatory elements at the lung cancer-specific DKK1 locus[J].Oncol Lett,2018,16(1):137-144.
14 Sato N,Yamabuki T,Takano A,et al.Wnt inhibitor Dickkopf-1 as a target for passive cancer immunotherapy[J].Cancer Res,2010,70(13):5326-5336.
15 Sheng SL,Huang G,Yu B,et al.Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer[J].Clin Chem,2009,55(9):1656-1664.
16 Li S,Qin X,Guo X,et al.Dickkopf-1 is oncogenic and involved in invasive growth in non small cell lung cancer[J].PLoS One,2013,8(12):e84944.
17 Kimura H,Fumoto K,Shojima K,et al.CKAP4 is a Dickkopf1 receptor and is involved in tumor progression[J].J Clin Invest,2016,126(7):2689-2705.
18 Zhang J,Zhang X,Zhao X,et al.DKK1 promotes migration and invasion of non-small cell lung cancer via β-catenin signaling pathway[J].Tumor Biology,2017,39(7):101042831770382.
19 Xiao XJ,Liu YW,Chen DD,et al.Differential expression of Dickkopf-1 among non-small cell lung cancer cells[J].Mol Med Rep,2015,12(2):1935-1940.
20 Na Y,Lee SM,Kim DS,et al.Promoter methylation of Wnt antagonist DKK1 gene and prognostic value in Korean patients with non-small cell lung cancers[J].Cancer Biomark,2012,12(2):73-79.
21 Xu H,Wu J,Chen B,et al.Serum Dickkopf-1(DKK1)is significantly lower in patients with lung cancer but is rapidly normalized after treatment[J].Am J Transl Res,2014,6(6):850-856.
22 Dong LL,Qu LY,Chu LY,et al.Serum level of DKK-1and its prognostic potential in non-small cell lung cancer[J].Diagn Pathol,2014,9(1):52.
23 Bhavanasi D,Speer KF,Klein PS.CKAP4 is identified as a receptor for Dickkopf in cancer cells[J].J Clin Invest,2016,126(7):2419-2421.
24 Shen T,Chen Z,Qiao J,et al.Neutralizing monoclonal antibody against Dickkopf2 impairs lung cancer progression via activating NK cells[J].Cell Death Discov,2019,5:123.
25Yue W,Sun Q,Dacic S,et al.Downregulation of Dkk3 activates-catenin/TCF-4 signaling in lung cancer[J].Carcinogenesis,2008,29(1):84-92.
26 雷艳荣,张静琼,王纯.非小细胞肺癌血清DKK3基因启动子甲基化的临床意义[J].国际检验医学杂志,2013,34(11):1450-1452.
27 Li Y,Ye X,Tan C,et al.Axl as a potential therapeutic target in cancer:role of Axl in tumor growth,metastasis and angiogenesis[J].Oncogene,2009,28(39):3442-3455.
28 Sima J,Piao Y,Chen Y,et al.Molecular dynamics of Dkk4 modulates Wnt action and regulates meibomian gland development[J].Development,2016,143(24):4723-4735.
29 Patel S,Barkell AM,GuptaD,et al.Structural and functional analysis of Dickkopf 4(Dkk4):new insights into Dkk evolution and regulation of Wnt signaling by Dkk and Kremen proteins[J].J Biol Chem,2018,293(31):12149-12166.
30 Wang Z,Ma LJ,Kang Y,et al.Dickkopf-3(Dkk3)induces apoptosis in cisplatin-resistant lung adenocarcinoma cells via the Wnt/β-catenin pathway[J].Oncol Rep,2015,33(3):1097-106.
31 Cheng R,Lu C,Zhang G,et al.Overexpression of miR-203 increases the sensitivity of NSCLC A549/H460 cell lines to cisplatin by targeting Dickkopf-1[J].Oncol Rep,2017,37(4):2129-2136.
32 Salim H,Zong D.DKK1 is a potential novel mediator of cisplatin-refractoriness in non-small cell lung cancer cell lines[J].BMC Cancer,2015,15(1):628.
33 Mistry SJ,Oh WK.New paradigms in microtubule-mediated endocrine signaling in prostate cancer[J].Mol Cancer Ther,2013,12(5):555-566.
34 Marzo I,Naval J.Antimitotic drugs in cancer chemotherapy:Promises and pitfalls[J].Biochem Pharmacol,2013,86(6):703-710.
35 Kuczynski EA,Sargent DJ,Grothey A,et al.Drug rechallenge and treatment beyond progression-implications for drug resistance[J].Nat Rev Clin Oncol,2013,10(10):571-587.
36 Tao L,Huang G,Chen Y,et al.DNA methylation of DKK3 modulates docetaxel chemoresistance in human nonsmall cell lung cancer cell[J].Cancer Biother Radiopharm,2015,30(2):100-106.
37 Yang X,Liu Y,Li W,et al.DKK4-knockdown enhances chemosensitivity of A549/DTX cells to docetaxel[J].Acta Biochim Biophys Sin(Shanghai),2017,49(10):899-906.
38 郭梦楠.SLL-1A-16在肺癌细胞中抗肿瘤活性及其作用机制研究[D].沈阳:辽宁大学,2019.
39 杨茜.左旋一叶萩碱诱导A549细胞株甲基化改变的研究[D].芜湖:皖南医学院,2017.
40 Papatriantafyllou M,Moldenhauer G,Ludwig J,et al.Dickkopf-3,an immune modulator in peripheral CD8 T-cell tolerance[J].Proc Natl Acad Sci U S A,2012,109(5):1631-1636.
41 Suzawa K,Shien K,Peng H,et al.Distant bystander effect of REIC/DKK3 gene therapy through immune system stimulation in thoracic malignancies[J].Anticancer Res,2017,37(1):301-308.
42 Xiao Q,Wu J,Wang W J,et al.DKK2 imparts tumor immunity evasion through β-catenin-independent suppression of cytotoxic immune-cell activation[J].Nat Med,2018,24(3):262-270.

[1]	闫䶮, 侯利芳, 李任飞, 闫鹏, 王月东, 郑玉婷. ^99mTc-HYNIC-MPG在体非小细胞肺癌分子分型研究[J]. 实用肿瘤学杂志, 2020, 34(5): 412-417.
[2]	陈灿, 张艳玲, 刘小庆, 冉凤伟. miR-182对直肠癌细胞增殖、侵袭及Foxo3a/Wnt/β-catenin通路的调节作用[J]. 实用肿瘤学杂志, 2020, 34(4): 328-333.
[3]	孙亚娟, 姜智允, 尚乃舰, 孙庆鑫, 陆佩欧. 双源CT能量成像在评估非小细胞肺癌纵隔淋巴结转移中的应用价值[J]. 实用肿瘤学杂志, 2019, 33(6): 531-535.
[4]	孙立春,李丹丹,李净,于凤玲. CCDC8和TGF-β1在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2019, 33(3): 215-221.
[5]	李万祯, 殷俊, 李萍, 林晓辉, 张国前, 张书旭. iR-17在非小细胞肺癌放射抗拒细胞中的表达及作用研究[J]. 实用肿瘤学杂志, 2018, 32(5): 391-397.
[6]	蔡静, 候玥. 非小细胞肺癌患者血清miR-195的表达及其临床意义[J]. 实用肿瘤学杂志, 2018, 32(5): 415-419.
[7]	崔晓燕, 涂青, 甘建辉. 纳布啡与羟考酮自控镇痛对非小细胞肺癌患者术后免疫因子水平影响的比较[J]. 实用肿瘤学杂志, 2018, 32(4): 309-314.
[8]	雷俊华, 许冠华, 曾江正, 黄芬, 何志惠, 卢彦达. 隐丹参酮联合顺铂抗非小细胞肺癌NCI-H1975细胞JAK2/STAT3机制研究[J]. 实用肿瘤学杂志, 2018, 32(3): 198-202.
[9]	翟可可, 高媛媛, 冯晓, 许静文, 宫玉芳, 孟庆威. 术后辅助化疗后复发转移与初次诊断的IV期NSCLC一线化疗疗效分析[J]. 实用肿瘤学杂志, 2018, 32(2): 107-111.
[10]	杜夜生, 胡松柳, 徐向英. 非小细胞肺癌寡转移的立体定向放射治疗研究[J]. 实用肿瘤学杂志, 2018, 32(2): 154-158.
[11]	孙明亮, 徐建宇, 徐向英. 早期非小细胞肺癌立体定向放疗的相关研究[J]. 实用肿瘤学杂志, 2018, 32(1): 53-56.
[12]	代欣综述, 张大昕审校. 非小细胞肺癌抗血管生成治疗研究现状[J]. 实用肿瘤学杂志, 2017, 31(5): 472-476.
[13]	胡海峰, 冯谢敏, 乔健, 段伟, 刘宁宁, 孙晓东. miR-345在非小细胞肺癌中的表达及临床意义[J]. 实用肿瘤学杂志, 2017, 31(2): 117-122.
[14]	张锐，王智煜，王帅，赵晖. 重组人血管内皮抑素联合NP方案治疗初诊晚期非小细胞肺癌骨转移疗效及对血清VEGF表达的影响[J]. 实用肿瘤学杂志, 2016, 30(6): 527-522.
[15]	任凤海,王丹丹,王俊峰,徐海,徐世东. 单孔与单操作孔电视辅助胸腔镜手术治疗ⅠA期非小细胞肺癌的临床对比研究[J]. 实用肿瘤学杂志, 2016, 30(4): 327-331.

Dickkopf家族蛋白在非小细胞肺癌中的作用机制和
治疗应用的研究进展

Research progress on the mechanism and treatment of Dickkopf family protein in non-small cell lung cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价